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Abstract
We previously established a role for the second messenger
ceramide in protein kinase R (PKR)-mediated articular cartilage
degradation. Ceramide is known to play a dual role in collagen
gene regulation, with the effect of ceramide on collagen
promoter activity being dependent on its concentration.
Treatment of cells with low doses of sphingomyelinase
produces small increases in endogenous ceramide. We
investigated whether ceramide influences articular chondrocyte
matrix homeostasis and, if so, the role of PKR in this process.
Bovine articular chondrocytes were stimulated for 7 days with
sphingomyelinase to increase endogenous levels of ceramide.
To inhibit PKR, 2-aminopurine was added to duplicate cultures.
De novo sulphated glycosaminoglycan and collagen synthesis
were measured by adding [35S]-sulphate and [3H]-proline to the
media, respectively. Chondrocyte phenotype was investigated
using RT-PCR and Western blot analysis. Over 7 days,
sphingomyelinase increased the release of newly synthesized
sulphated glycosaminoglycan and collagen into the media,
whereas inhibition of PKR in sphingomyelinase-treated cells
reduced the level of newly synthesized sulphated
glycosaminoglycan and collagen. Sphingomyelinase treated
chondrocytes expressed col2a1 mRNA, which is indicative of a
normal chondrocyte phenotype; however, a significant reduction
in type II collagen protein was detected. Therefore, small
increments in endogenous ceramide in chondrocytes appear to
push the homeostatic balance toward extracellular matrix
synthesis but at the expense of the chondrocytic phenotype,
which was, in part, mediated by PKR.
Introduction
The signalling molecule ceramide belongs to a family of highly
hydrophobic molecules containing a variable length fatty acid
linked to sphingosine [1]. As well as its established role in
membrane structure, many studies have now shown that cera-
mide is a key second messenger, activating a number of intra-
cellular signalling cascades that are implicated in a wide range
of cellular functions such as proliferation, differentiation,
necrosis and apoptosis [2-4]. Interestingly, Sabatini and cow-
orkers [5,6] recently implicated ceramide signalling in the reg-
ulation of proteoglycan degradation and mRNA expression of
matrix metalloproteinases (MMPs) 1, 3 and 13 in rabbit articu-
lar chondrocytes. Furthermore, we demonstrated that applica-
tion of exogenous ceramide induces articular cartilage
degradation, which is, in part, mediated through protein kinase
R (PKR) [7,8]. Treatment of cartilage explants with the short
chain, cell permeable ceramide analogue C2-ceramide
resulted in PKR-mediated increases in chondrocyte death and
release of proteoglycans and pro- and active MMP-2. In addi-
tion, ceramide has been shown to activate PKR in leukaemia
cell lines, and at high concentrations it results in PKR-medi-
ated inhibition of protein synthesis [4]. Thus, ceramide signal-
ling, via the PKR pathway, may play a pivotal role in articular
cartilage metabolism.
Endogenous ceramide is produced via two main pathways:
the catabolic pathway involving hydrolysis of the membrane
lipid sphingomyelin by endosomal acidic and membrane-Page 1 of 11
(page number not for citation purposes)
2AP = 2-aminopurine; DMEM = Dulbecco's modified eagle's medium; DMMB = dimethylmethylene blue; ECM = extracellular matrix; GAPDH = glyc-
eraldehyde-3-phosphate dehydrogenase; ITS = insulin-transferrin-sodium selenite; LDH = lactate dehydrogenase; MMP = matrix metalloproteinase; 
PKR = protein kinase R; RT-PCR = reverse transcription polymerase chain reaction; sGAG = sulphated glycosaminoglycan; SMase = sphingomyeli-
nase; TNF = tumour necrosis factor.
Arthritis Research & Therapy    Vol 8 No 4    Gilbert et al.bound neutral sphingomyelinases (SMases); and de novo syn-
thesis [3] (Figure 1). Hydrolysis of sphingomyelin at the exter-
nal leaflet of the plasma membrane by the application of
exogenous bacterial SMase, an enzyme with properties similar
to those of neutral SMase, leads to a transient increase in
intracellular ceramide formation [9], the magnitude of which
increases with increasing doses of SMase [10]. Treatment of
cells with tumour necrosis factor (TNF)-α also increases cellu-
lar ceramide but in a more sustained manner [10]. Increased
levels of intracellular ceramide can create a positive feedback
loop to amplify ceramide production further via the activation
of endogenous SMases [11]. Once generated, ceramide tran-
siently accumulates within the cell or is converted into various
metabolites such as sphingosine and sphingosine-1-phos-
phate (Figure 1) [12]. Cell responses to ceramide depend
upon the engagement of downstream effectors, the cell micro-
environment and concomitant activation of enzymes that con-
vert ceramide into other metabolites. In some cell types,
raising the intracellular levels of ceramide is sufficient to
induce stress responses such as apoptosis and cell cycle
arrest [9]. Therefore, within the cell a dynamic balance must
exist between the levels of ceramide and sphingosine, which
promote antigrowth effects, and sphingosine-1-phosphate,
which promotes proliferation (Figure 1) [3,9,12-15]. Cerami-
dase converts ceramide to sphingosine and thus contributes
to this balance [13]. Absence of ceramidase causes Farber's
disease, in which an accumulation of excess ceramide within
the cartilage and bone leads to joint pain and arthritis-like joint
degeneration [16].
Evidence suggests that there is a dual role for sphingolipids in
collagen gene regulation, supporting the existence of a sphin-
golipid rheostat [15]. Low concentrations of ceramide stimu-
late type I collagen promoter activity in fibroblasts, whereas
high concentrations of ceramide potently inhibit collagen gene
transcription and decrease collagen protein production in
fibroblasts and hepatic stellate cells [17-19]. To our knowl-
edge, no studies have been conducted to investigate the
effect of ceramide accumulation on chondrocyte extracellular
matrix (ECM) homeostasis. However, the research described
above suggests that increases in endogenous ceramide may
affect cartilage ECM protein transcription and translation, as
well as activating degradative pathways that are involved in the
pathogenesis of diseases such as osteoarthritis. The aims of
the present study were therefore to investigate the effect of
increasing the levels of endogenous ceramide on articular
chondrocyte homeostasis and to determine whether any cera-
mide-induced changes in matrix metabolism are mediated via
the PKR signalling pathway.
Materials and methods
Materials
All chemicals were obtained from Sigma (Poole, UK) unless
otherwise stated and were of analytical grade or above. Cul-
ture medium consisted of Dulbecco's modified eagle's
medium (DMEM; DMEM-Glutamax-I™, Invitrogen, Paisley, UK)
supplemented with 100 U/ml penicillin, 100 µg/ml streptomy-
cin, 50 µg/ml ascorbate-2-phosphate and 1× insulin-transfer-
rin-sodium selenite (ITS). For radiolabelling experiments,
DMEM-Glutamax-I™ was replaced with a 1:1 mixture of
DMEM-Glutamax-I™ and Hams F12 media.
Primary articular chondrocyte culture
Articular cartilage was taken from the metacarpalphalangeal
joint of 7-day-old calves within 12 hours of slaughter using a
scalpel, and full-depth cartilage explants (20–70 mg) were cul-
tured overnight at 37°C in a humidified atmosphere of 5% car-
bon dioxide and 95% air in 1 ml of DMEM-Glutamax-I™
supplemented with 10% foetal calf serum. DMEM-Glutamax-
I™ containing foetal calf serum was removed and chondro-
cytes isolated as previously described [20]. Following isola-
tion, chondrocytes were cultured (1 × 106 cells/well of a 24-
well plate) overnight at 37°C in serum-free DMEM-Glutamax-
I™ supplemented with ITS in order to maintain their chondro-
cytic phenotype [21] and prevent serum withdrawal activation
of signalling pathways [22]. To increase endogenous levels of
ceramide, chondrocytes were stimulated for up to 10 days
with bacterial SMase (0.1–1.0 U/ml) [10]. Media and treat-
ments were refreshed at 7 days if cultures were extended to
10 days. To investigate the role of PKR in SMase-mediated
responses, the PKR inhibitor 2-aminopurine (2AP; 1 mmol/l)
was added to duplicate cultures 1 hour before and during the
addition of treatments. This concentration inhibits activation of
PKR in a number of cell types [4,8,23-26] and does not affect
chondrocyte viability [8]. Following treatment, media was
removed and stored at -20°C and 200 µl ice-cold extract
buffer (0.9% Triton X-100) containing protease inhibitors (1
µmol/l leupepstatin hemisulphate, 150 nmol/l aprotinin, 0.5
mmol/l EDTA disodium salt, 500 µmol/l AEBSF HCl, 1 µmol/l
E64; Merck Biosciences, Nottingham, UK) and phosphatase
inhibitors (phosphatase inhibitor cocktail set II, according to
manufacturer's instructions; Merck Biosciences, Nottingham,
UK) was added to the cells. Cell extracts were stored at -80°C
for future analysis.
Cytotoxicity assay and total cell number
Cell death was assessed using the CytoTox 96® assay
(Promega, Southampton, UK), which quantitatively measures
lactate dehydrogenase (LDH) present in the culture media that
has been released upon natural lysis of cells during the culture
period [8,27]. This assay measures both primary and second-
ary necrotic cell death. Differences in the release of LDH asso-
ciated with culture treatment were expressed as absorbance
units. The total cell number, at the end of each treatment, was
also determined using the CytoTox 96® assay. This assay can
be used to measure indirectly the LDH activity present in the
cytoplasm of cells that are intact at the end of the culture
period. Cell quantification, therefore, occurs following lysis of
the cells by the addition of extract buffer. The number of cellsPage 2 of 11
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represents LDH activity [10].
Analysis of proteoglycan release
The amount of sulphated glycosaminoglycan (sGAG) released
into the medium of chondrocyte cultures was measured using
the dimethylmethylene blue (DMMB) assay using chondroitin-
4-sulphate-C from shark cartilage as a standard, as described
previously [28]. Differences in the release of sGAG associ-
ated with culture treatment were expressed as micrograms of
GAG released per cell.
Determination of protein concentration
The protein concentration of cell extracts after 24 hours of
treatments was determined using the BCA method, in accord-
ance with the manufacturer's instructions (Perbio Science,
Cramlington, UK).
Analysis of de novo matrix synthesis using [35S]-
sulphate and [3H]-proline radiolabelling
To measure newly synthesized protein and sGAGs, chondro-
cytes (4 × 105 cells/well of a 48-well plate) were treated with
sphingomyelinase (0.1 U/ml) in the presence of 20 µCi/ml of
[3H]-proline and 10 µCi/ml [35S]-sulphate (GE Healthcare,
Chalfont St Giles, UK). At the end of the treatment period,
Figure 1
Metabolic pathways involved in the production of endogenous ceramide. Endogenous ceramide is produced via 2 main mechanisms: a catabolic 
pathway, involving the hydrolysis of the membrane lipid sphingomyelin by endosomal acidic and membrane-bound neutral SMases; and de novo syn-
thesis. TNF-α can increase cellular ceramide via both mechanisms. The rise in ceramide can create a positive feedback loop to amplify ceramide pro-
duction further via the activation of SMases. Once generated, ceramide can transiently accumulate within the cell or be converted into various 
metabolites such as sphingosine and sphingosine-1-phosphate. Cell responses to ceramide will therefore depend on the engagement of down-
stream effectors, the cell microenvironment and concomitant activation of enzymes that convert ceramide into other metabolites. CoA, coenzyme A; 
ER, endoplasmic reticulum; SMase, sphingomyelinase; TNF, tumour necrosis factor.Page 3 of 11
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cell extracts using Ultrafree®-MC centrifugal filter units, in
accordance with the manufacturer's instructions (Millipore,
Watford, UK). Incorporated [35S] radioactivity in the culture
media and cell extracts was counted (Beckman Scintillation
Counter; Beckman Coulter, High Wycombe, UK) as a meas-
ure of de novo sGAG synthesis.
De novo collagen synthesis was determined by digesting
labelled protein in media and cell extracts with 8U bacterial
collagenase (Worthington's Type 3 collagenase; Lorne Labo-
ratories, Reading, UK) overnight at 37°C [29]. Digested colla-
gen fragments were removed using Ultrafree®-MC filter units
and the remaining undigested [3H] counts taken as a measure
of noncollagenous protein. Collagenous protein was calcu-
lated using the following equation: collagen (counts/min) =
total protein (counts before digestion) – noncollagenous pro-
tein (counts after digestion).
RNA extraction, cDNA synthesis and PCR
To investigate chondrocyte phenotype and to determine
whether acidic and neutral SMase are expressed in articular
chondrocytes, RT-PCR was performed. Chondrocytes were
treated with or without SMase (0.1 U/ml), placed into TRI-
ZOL® (1 × 106 cells/ml) and total RNA was extracted, in
accordance with the manufacturer's instructions (Invitrogen,
Paisley, UK). RNA samples were DNase (Ambion, Hunting-
don, UK) treated to remove genomic DNA, in accordance with
the manufacturer's protocol, and resuspended in 50 µl sterile
water. cDNA was generated in a single 20 µl reaction from 11
µl RNA sample using 250 ng random hexamers (0.5 mg/ml;
Promega) and Superscript II reverse transcriptase (200 units),
in accordance with the manufacturer's instructions (Invitro-
gen). cDNA integrity and lack of genomic DNA contamination
were confirmed by PCR using primers to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH [GenBank:U85042];
Table 1). PCR primers (Table 1) designed to acidic SMase
[GenBank:AF325550], neutral SMase [Gen-
Bank:NM031360], type IIA and IIB collagen [30], and Sox9
[GenBank:AF278703] sequences were used to amplify
cDNA derived from bovine articular chondrocytes. cDNA or
water controls (1 µl) were amplified for 25–30 cycles in a 12.5
µl reaction volume (0.2 units Taq polymerase [Promega], 200
µmol/l of each dNTP, 1.5–2.5 mmol/l MgCl2 and 0.2–0.4
µmol/l of each primer; Table 1) using the following cycling
parameters: 94°C for 30 s; 58°C or 60°C for 30 s; and 72°C
for 1 min. Amplified products were separated alongside a 100
base pair DNA ladder (Promega) on 1–2% agarose gels, con-
taining ethidium bromide (10 µg/ml).
Quantitative PCR
Type II collagen and aggrecan gene expression were meas-
ured by quantitative PCR (qPCR). cDNA was produced as
detailed above and qPCR carried out using an ABI 7700
Sequence Detection System, in accordance with the manu-
facturer's instructions (Applied Biosystems, Warrington, UK)
using 300 nmol/l forward and reverse primers and 200 nmol/l
probe (5' 6-carboxyfluorescein and 3' 6-carboxytetramethyl-
rhodamine). The GAPDH gene was used as an endogenous
control to normalize for differences in the amount of total RNA
present in each sample; GAPDH primers (forward: 5'-
GGCATCGTGGAGGGACTTATGA-3'; reverse: 5'-CAGAA-
GACTGTGGATGGCCC-3') and probe (5'-CACTGTC-
CACGCCATCACTGC-3') were purchased from Applied
Biosystems. Primers and probes to type II collagen and aggre-
can were as previously described [31].
Western blot analysis of type II collagen
To further investigate the phenotype of bovine chondrocytes
following culture in the presence and absence of SMase,
Table 1
PCR primers
Gene Strand Sequence Annealing temp (°C) MgCl2 (mmol/l) Product size (bp) Reference/GenBank 
accession number
Acidic SMase Forward 5'-ATCGGCCTTAATCCTGGTGA-3' 58 2.5 151 AF325550
Reverse 5'-GACTGGACACGGAGAGGGC-3'
Neutral SMase Forward 5'-TTGGCAGTGGCCTCTGTGTG-3' 58 2.5 151 NM031360
Reverse 5'-AGTCCGCTTAGATGGAGCACC-3'
GAPDH Forward 5'-TGGTCACCAGGGCTGCTTTTA-3' 60 2.5 746 U85042
Reverse 5'-CGCCTGCTTCACCACCTTCT-3'
Sox9 Forward 5'-GGGCGAGCCGGACCTGAAGAA-3' 53 1.5 321 AF278703
Reverse 5'-CGCTCCGCCTCCTCCACGAAC-3'
Col2a1 Forward 5'-GCCTCGCGGTGAGCCATGATC-3' 60 1.5 IIA: 472 Valcourt and 
coworkers [30]
Reverse 5'-CTCCATCTCTGCCACGGGGT-3' IIB: 268
*Unless previously published, primers were designed to GenBank sequences using Primer Express® software (Applied Biosystems). bp, base pairs; 
SMase, sphingomyelinase.Page 4 of 11
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[32]. Cell associated material and media samples (from equiv-
alent cell numbers) were reduced (5% β-mercaptoethanol)
and resolved on 7.5% (weight/vol) SDS-polyacrylamide gels
and transferred subsequently to PVDF membrane (Immobilon;
Millipore). Binding of our monclonal antibody to type II colla-
gen (AVT6E3) [33] and horseradish peroxidase conjugated
anti-mouse IgG was detected using enhanced chemilumines-
cence reagents (GE Healthcare) on Hyperfilm-ECL (GE
Healthcare).
Figure 2
Effect of sphingomyelinase on chondrocyte function. (a) Sphingomyelinase treatment dose dependently induces cell death and decreases cell 
number. Chondrocytes were cultured for 24 hours in the presence of SMase (0–1.0 U/ml). Cell death and cell number were assessed using the 
CytoTox 96® assay (Promega), which quantitatively measures lactate dehydrogenase released into the media upon cell death during the culture 
period or upon lysis of living cells at the end of the culture period. Data shown are mean absorbance units (492 nm) ± standard error. ** P < 0.01 
versus control. (b) Short-term SMase treatment induces proteoglycan release from articular chondrocytes. Chondrocytes were cultured for 24 hours 
in the presence of SMase (0–1.0 U/ml). Media was analyzed for release of sGAGs using the DMMB assay. Differences in release of sGAG associ-
ated with culture treatment are expressed as mean sGAG released per cell (mg/ml) ± standard error. * P < 0.05; ** P < 0.01. (c) SMase dose 
dependently increases cellular protein content. Following 24 hours of treatment with increasing doses of SMase, cells (with cell-associated matrix 
proteins) were solubilized with 0.9% Triton X-100 and the protein content (mg/ml) determined using the BCA assay (Pierce). Data are presented as 
mean ± standard error. * P < 0.05; *** P < 0.001, versus control. (d) Long-term SMase treatment reduces cell proliferation. Chondrocytes were cul-
tured for 1–7 days and the effect of SMase (0.1 U/ml) on cell number determined using the CytoTox® assay. Data shown are mean absorbance units 
(492 nm) ± standard error. * P < 0.05 versus control at equivalent time point. (e) Long-term SMase treatment induces proteoglycan release from 
articular chondrocytes. Chondrocytes were cultured in the presence of SMase (0.1 U/ml) for 7 days. The amount of sGAG released into the media 
per cell was determined as above. Data are presented as mean ± standard error. * P < 0.05. DMMB, dimethylmethylene blue; sGAG = sulphated 
glycosaminoglycan; SMase, sphingomyelinase.Page 5 of 11
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Data are representative of at least three independent experi-
ments except for the radiation experiment, which was repeated
twice. Data are presented, following normalization to cell
number, as mean ± standard error (n ≥ 3), tested for normality
and equal variances, and analyzed by Student's two-sample t
test (Minitab Statistical Software; Minitab Ltd, Coventry, UK).
Treatments were compared with untreated control cells and
differences were considered significant at the 5% level (P <
0.05).
Results
Effect of increasing doses of exogenous 
sphingomyelinase on chondrocyte function
Because there are no previous studies investigating the effect
of exogenous SMase on chondrocyte function, we first deter-
mined its effect at different concentrations. Chondrocytes
were cultured with a range of SMase concentrations (0–1.0
U/ml) for 24 hours and the cells assessed for viability, sGAG
and protein release (Figure 2). SMase caused a dose-depend-
ent increase in chondrocyte death with a concomitant
decrease in cell number (Figure 2a). The amount of sGAG
released into the media following 24 hours of treatment was
measured using the DMMB assay (Figure 2b). SMase treat-
ment caused a significant, dose-dependent increase in sGAG
release into the media. Cell extracts with associated matrix
from SMase-treated cultures contained significantly more pro-
tein than did untreated controls (0.1 U/ml, P < 0.001; 0.5 U/
ml, P = 0.024; Figure 2c).
A dose of 0.1 U/ml was chosen for further study because this
caused a minimal level of cell death at 24 hours (control 0.17
± 0.0003 versus SMase 0.2 ± 0.005). An identical experiment
was thus performed and cells cultured for 1–7 days. Cell
number, cell death and the amount of sGAG released into the
media over this period were measured. Over 7 days, an equiv-
alent level of cell death was observed in all cultures regardless
of treatment and did not exceed 10–15% of the total cell
number (data not shown). Despite this, over the same culture
period, significantly fewer cells were found in SMase-treated
cultures than in controls (P = 0.049), suggesting reduced pro-
liferation (Figure 2d). In addition, SMase significantly
Figure 3
Sphingomyelinase increases de novo sGAG and collagen synthesis in articular chondrocytes. Bovine articular chondrocytes were cultured for 7 
days with 20 µCi/ml [3H]-proline and 10 µCi/ml [35S]-sulphate in the presence or absence of SMase (0.1 U/ml). At the end of the culture period, 
unincorporated label was removed and (a) [35S] counts (cpm) were measured in cell associated material and media as a measure of de novo sGAG. 
De novo collagen synthesis was determined by digesting labelled protein in media and cell extracts with 8U bacterial collagenase overnight at 37°C. 
Digested collagen fragments were removed using Ultrafree®-MC filter units and remaining [3H] counts taken as a measure of noncollagenous pro-
tein. (b) Collagenous protein was calculated using the following equation: collagen (cpm) = total protein ([3H] counts before collagenase digestion) 
– noncollagenous protein (counts remaining after collagenase digestion). Data are normalized to cell number and presented as mean ± standard 
error. * P < 0.05 versus control. cpm, counts/min; sGAG, sulphated glycosaminoglycan.Page 6 of 11
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0.046; Figure 2e).
Effect of SMase on de novo sGAG and collagen 
synthesis
To determine whether the observed SMase-mediated
increase in sGAG and protein release into the media was due
to increased synthesis, radiolabelling experiments were per-
formed. Cultures were treated with SMase (0.1 U/ml) for 7
days in the presence of 10 µCi/ml [35S]-sulphate and 20 µCi/
ml [3H]-proline. In addition to measurements of total protein,
cell extracts and media were digested with collagenase to
determine what proportion of the de novo protein synthesised
was collagen. At the end of the culture period, unincorporated
label was removed and [35S] counts (counts/min) measured in
cell associated material and media as a measure of de novo
sGAG (Figure 3a). SMase did not significantly increase the
amount of newly synthesized sGAG associated with the cell
but did significantly increase the level of newly synthesized
sGAG in the media (P = 0.017). SMase significantly
enhanced the amount of de novo collagen released into the
media (P = 0.015; Figure 3b).
Investigation of chondrocyte phenotype following 
culture with SMase
Type II collagen is the major collagen component of articular
cartilage and is considered a marker for the differentiated
chondrocyte phenotype. Two forms are generated by alterna-
Figure 4
A differentiated chondrocyte phenotype is maintained but sphingomyelinase treatment reduces type II collagen expressioni i t i  t i y li  tr t t reduces type I  col agen expression. Bovine articular chondro-
cytes were cultured as monolayers for 7–10 days in ITS supplemented media in the presence or absence of SMase (0.1 U/ml). Where cultures were 
extended to 10 days, media and treatments were refreshed at day 7. (a) Equivalent numbers of cells and their associated matrix and (b) media were 
resolved on 7.5% (weight/vol) SDS-PAGE gels. Samples were analyzed for type II collagen by Western blotting using our monoclonal antibody 
(AVT6E3). In addition, cells cultured in the presence (+) or absence (-) of SMase (0.1 U/ml) for this period were placed into TRIZOL® (1 × 106 cells/
ml) and total RNA extracted, in accordance with the manufacturer's instructions. (c) cDNA was generated and PCR performed using primers to type 
IIA and IIB procollagen and Sox9. cDNA integrity was confirmed using primers to GAPDH. (d) The relative expression level, normalized to GAPDH, 
of aggrecan and type II collagen mRNAs was determined by quantitative PCR. Data are presented as mean ± standard error. α1(II), α1 chain type II 
collagen. bp, base pairs; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ITS, insulin-transferrin-sodium selenite; RT-PCR, reverse transcrip-
tion polymerase chain reaction; SMse, sphingomyelinase.Page 7 of 11
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and exclude exon 2, respectively. The shift from IIA to IIB
accompanies chondrocyte differentiation, whereas re-expres-
sion of IIA procollagen has been reported in osteoarthritic car-
tilage, indicating the potential reversion of the cells to a
chondroprogenitor cellular phenotype [34]. There was no
apparent difference in cell morphology with any of the treat-
ments. Following 7–10 days of culture, cell extracts with their
associated matrix and media were analyzed for type II collagen
by Western blotting (Figure 4). Control cells produced type II
procollagen, processing it (α1 [II]) and secreting it into the
media (Figure 4a,b), demonstrating that the differentiated
chondrocyte phenotype was maintained in our culture system.
In contrast, SMase treatment decreased the amount of type II
procollagen (Figure 4a,b) as well as resulting in a reduction in
the level of processed collagen in the media (Figure 4b). This
response was further enhanced at day 10 following an appli-
cation of fresh SMase at day 7. RT-PCR analysis of chondro-
cytes after 7 days showed that the mRNAs for the phenotypic
markers of articular cartilage chondrocytes, type IIB collagen
and Sox9 were expressed in both control and SMase treated
cells (Figure 4c). SMase treatment had no significant effect on
type II collagen or aggrecan mRNA expression normalized to
GAPDH (Figure 4d).
Effect of inhibiting activation of PKR on cartilage matrix 
homeostasis
The role of PKR in chondrocyte ECM homeostasis was inves-
tigated by treating duplicate cultures with the PKR inhibitor
2AP (Figure 5). Inhibition of PKR activity in untreated control
cells significantly increased the level of de novo collagen asso-
ciated with the cell (Figure 5a; P = 0.018) but had no effect
on the amount measured in the media (data not shown). Addi-
tion of 2AP in conjunction with SMase did not significantly
alter cell death, de novo collagen and sGAG associated with
the cell (data not shown), but significantly reduced the total
amount detected in the media compared with treatment with
SMase alone (collagen, P = 0.042; sGAG, P = 0.042; Figure
5b).
Both acidic and neutral sphingomyelinases are 
expressed by articular chondrocytes
To investigate whether bovine articular chondrocytes may
potentially signal via endogenous SMases, we determined
mRNA expression for acidic and neutral sphingomyelinase.
RT-PCR revealed that both acidic and neutral SMase mRNAs
are expressed by primary articular chondrocytes (Figure 6).
Discussion
This study demonstrates for the first time that ECM homeosta-
sis in articular cartilage chondrocytes can be profoundly
altered by triggering the ceramide signalling pathway. Over 24
hours, raising endogenous levels of ceramide in articular carti-
lage chondrocytes by treatment with 0.1 U/ml bacterial SMase
caused a dose-dependent increase in cell death with a con-
comitant decrease in cell number. This is in accordance with
the known role for ceramide in initiating a cellular stress
response resulting in cell death [12]. It should be noted that
the assay used to measure cell death in this study detects loss
of membrane integrity and thus measures necrosis, either pri-
mary or secondary (cultured cells that are undergoing apopto-
sis in vitro eventually undergo secondary necrosis). Therefore,
further studies are necessary to determine the extent of apop-
totic cell death. Over the extended culture period, SMase
treatment resulted in a further reduction in cell number com-
pared with that in control cultures, with the majority of the
decrease occurring in the early stages of the treatment; there-
after the rate of proliferation was similar to that in controls (Fig-
ure 1d). Because there was no concomitant increase in cell
death, this suggests that SMase treatment also decreased
chondrocyte proliferation. This in accordance with studies in
human keratinocytes, which have shown that a rapid (15 min-
utes) but transient (returning to baseline by 1 hour) increase in
endogenous ceramide occurs following treatment with 0.1 U/
ml neutral SMase followed by reduced cellular proliferation
Figure 5
PKR is involved in cartilage matrix homeostasis. To determine whether 
PKR mediates the observed changes in chondrocyte matrix homeosta-
sis, PKR activity was inhibited by adding 1 mmol/l 2AP to duplicate cul-
tures. (a) Inhibition of PKR in untreated, control cells caused an 
increase in cell associated collagen. (b) Addition of 2AP to sphingomy-
elinase-treated cultures resulted in a significant reduction in the amount 
of de novo sGAG and collagen in the media. Data are presented as 
mean ± strandard error. * P < 0.05. 2AP, 2-aminopurine; cpm, counts/
min; PKR, protein kinase R; sGAG, sulphated glycosaminoglycan.Page 8 of 11
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the present study [35].
Data obtained from the DMMB assay indicated that SMase
increased the release of sGAG from articular chondrocytes.
Because this assay does not discriminate between whole
sGAG and degraded sGAG fragments, we used incorporation
of [35S] to determine whether low concentrations (0.1 U/ml) of
exogenous SMase affected sGAG synthesis or degradation.
As well as increasing sGAG synthesis, SMase also signifi-
cantly enhanced the level of de novo collagen and total protein
in the media over seven days of culture, suggesting that
SMase acts on chondrocytes to increase expression of ECM
components. The hydrolysis of sphingomyelin by the action of
SMases is the primary mechanism for rapidly increasing cera-
mide levels in the cell [36]. As discussed above, at the con-
centration (0.1 U/ml) used, SMase induces a rapid but
transient rise in endogenous ceramide in human keratinocytes
[35]. Our data correlate with recent studies in fibroblasts that
showed that low doses of ceramide stimulate collagen pro-
duction [15]. This is contrast to the effect caused by high cera-
mide, which is thought to inhibit collagen production
[15,17,18] because of its conversion to sphingosine-1-phos-
phate or other inhibitory intermediates, thus promoting antice-
ramide affects [15].
When chondrocytes are cultured as monolayers on plastic
they rapidly de-differentiate, losing expression of type II colla-
gen. More specifically they shift their expression from type IIB
to type IIA procollagen [37]. Our monolayer cultures supple-
mented with ITS retained expression of the normal chondro-
cyte markers Sox9, aggrecan and type IIB collagen. These
were still expressed by SMase-treated chondrocytes with no
detectable expression of type IIA mRNA. However, SMase
reduced type II collagen protein expression (Western blot),
despite increasing total collagen production (3[H]-proline
incorporation) and maintaining col2a1 mRNA expression
(qPCR). Therefore, although low levels of endogenous cera-
mide in chondrocytes appeared to push the homeostatic bal-
ance toward ECM synthesis, which is in accordance with
studies in fibroblasts [15], this may have been at the expense
of type II collagen expression.
Preliminary work within our laboratory suggests that the
SMase-induced increase in total collagen production is not
due to increases in type I or III collagen, but further investiga-
tion is clearly warranted. We propose that small increases in
cellular ceramide, as mimicked here, may contribute to the
increases in proteoglycan and collagen synthesis [38-40] that
are observed in the 'biosynthetic phase' in early osteoarthritis
[8]. Given that excessive ceramide accumulation within carti-
lage is known to produce an osteoarthritis-like phenotype [16],
we hypothesize that treatment of chondrocytes with high
doses of SMase would result in an accumulation of endog-
enous ceramide levels within the cells and that it is this that
signals downstream to promote cartilage degradative events.
Figure 6
Both neutral and acidic SMase mRNAs are expressed by articular cartilage chondrocytes. Following 24 hours of culture, cells were placed into TRI-
ZOL® (1 × 106 cells/ml) and total RNA extracted, in accordance with the manufacturer's instructions. cDNA was generated (n = 4) and PCR per-
formed using primers specific to GAPDH, or acidic or neutral SMase (Table 1). Amplified products were separated alongside a 100 bp DNA ladder 
(L) on 1–2% agarose gels, containing ethidium bromide (10 µg/ml). Product sizes (bp) are indicated. bp, base pairs; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; PCR, polymerase chain reaction; SMase, sphingomyelinase.Page 9 of 11
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degeneration is supported by our earlier studies in which
application of C2-ceramide increased MMP expression and
activation and proteoglycan release from articular cartilage
explants [8]. Thus, further investigations to relate levels of
ceramide, sphingosine and sphingosine-1-phosphate to
chondrocyte ECM synthesis and degradation are clearly
needed to determine how the current data fit into the notion of
a 'sphingolipid rheostat' [13].
Because our previous studies showed that the protein kinase
PKR plays a pivotal role in cartilage homeostasis [8], we inhib-
ited PKR activity to determine whether PKR is involved in the
observed changes in matrix synthesis. In control cells, inhibi-
tion of PKR caused a significant increase in de novo protein
synthesis found within the cell and associated matrix but no
change in the level released into the media. This is in keeping
with the known role played by PKR as an inhibitor of translation
[41]. However, inhibition of PKR activity in SMase-treated
chondrocytes significantly reduced the amount of newly syn-
thesized sGAG and collagen detected in the media, suggest-
ing a role for PKR in SMase-induced matrix synthesis.
Because high levels of ceramide have previously been shown
to result in PKR-mediated inhibition of protein synthesis in a
leukaemia cell line [4], this would suggest that a complex inter-
play of signalling pathways are involved in SMase-mediated
PKR signalling in chondrocytes, the exact nature of which
remains to be elucidated.
Finally, we showed, for the first time, that articular chondro-
cytes can express both acidic and neutral SMases and so are
able, given the appropriate external signal, to raise levels of
endogenous ceramide. It has been shown that TNF-α can
increase cellular ceramide levels via the de novo pathway as
well as by binding to its membrane receptor (TNFR55), caus-
ing activation of neutral or acidic SMase [36,42,43]. Depend-
ing on which SMase is activated, an inflammatory (neutral
SMase) or apoptotic (acidic SMase) response then occurs.
Because TNF-α levels are elevated in arthritis and TNFR55
expression is increased in arthritic disease [44], our future
studies will determine whether TNF-α-mediated activation of
neutral SMase and ceramide generation plays a role in carti-
lage degradation.
Conclusion
In the present study we found that sphingomyelinase, at low
concentration, stimulated ECM synthesis in articular chondro-
cytes, and this was in part mediated by PKR. Importantly, the
increase in collagen production was not due to increases in
type II collagen. Therefore, small increases in endogenous
ceramide in chondrocytes appear to push the homeostatic
balance toward ECM synthesis but at the expense of the
chondrocytic phenotype. We therefore hypothesize that dur-
ing the 'biosynthetic phase' in early osteoarthritis, the
observed increases in proteoglycan and collagen synthesis
may be due to a small increase in cellular ceramide triggered
by circulating cytokines such as TNF-α via activation of PKR.
Excessive ceramide accumulation may then play a role in the
later stages of cartilage degradation.
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